Lilly raises Mounjaro's UK list price by up to 170%, sparing NHS patients
The increase follows White House pressure to charge more abroad so US prices can fall, and it lands on Britons who pay for the drug themselves.
Eli Lilly will lift the UK list price of Mounjaro, its tirzepatide injection, by as much as 170% starting in September, the company said on Aug. 14, 2025 [1][3]. The headline number: a month of the highest dose goes from £122 to £330 [1][2].
List prices are the manufacturer's sticker figures, set before any rebates or discounts [1]. By dose, UK list prices now run from £92 to £122 a month and will sit between £133 and £330 from Sept. 1 [2]. Lilly described the change as "aligning the list price more consistently" with its other markets, after launching in Britain at a level "significantly below" the European average to avoid delays in NHS availability [1][3].
Two very different groups of patients
Britain's publicly funded health service is insulated from the increase. An NHS statement said the higher list price "will not affect NHS commissioning of tirzepatide in England for eligible people living with obesity, based on clinical priority, or as a treatment for type 2 diabetes" [2]. Lilly said the NHS negotiated its own discounted terms [1][3].
The people who face the new sticker price are private buyers, who make up most of the UK market. About 1.5 million people there are thought to use weight-loss drugs, more than half of them Mounjaro, and estimates put nine in 10 of those users as private payers buying through online sellers or high street pharmacies [3]. Because those sellers set their own prices and can bargain below list, the BBC noted the real-world effect on customers may end up smaller than the percentage suggests [3]. Lilly said it does not set private providers' prices and is working with them to preserve access [1][2]. What individual customers will actually pay has not been reported.
Why it matters for patients
Nothing in this announcement changes what Americans pay for Mounjaro today [2]. The US list price for a month's supply stands at $1,079.77 before insurance and rebates [2]. Lilly has framed the UK move as part of a broader rebalancing meant to make US prices lower over time, but no US cut tied to it has been disclosed [2].
The backdrop is a White House campaign. President Donald Trump revived a "most favored nation" pricing plan in May and in July sent letters to 17 drugmakers, Lilly among them, asking for steps to lower US prices by Sept. 29 [2]. Lilly said it shares the goal of spreading research costs more fairly, but called most favored nation the wrong mechanism and said it opposes planned tariffs on imported pharmaceuticals [2][3].
On an investor call, CEO David Ricks said parity between US and European pricing is desirable in the long run while noting that European governments "are not signing up to pay more for drugs" [1]. RAND Corp. figures cited by CNBC put US prescription drug prices at two to three times those in other developed countries on average, and up to 10 times higher than in some [2].
For patients in Britain paying privately, the practical question is what their pharmacy or online provider charges, which is not the list price and varies by seller [3]. Dr Sophie Dix of the online pharmacy Medexpress said her company was still working out how much of the rise would be passed through, and warned the "absolute worst-case scenario" would be people turning to the black market for the drug [3].
Dr Leyla Hannbeck of the Independent Pharmacies Association said she was "shocked and very disappointed," calling the increase "a real blow to patients at a time when more and more people, worried about their weight, are turning to jabs" [3]. She advised anyone already taking Mounjaro to speak with their pharmacy before acting [3].
What happens next
- Sept. 1, 2025: the new UK list prices take effect [1][2].
- By the same date, Lilly expects to make pricing adjustments in some other countries, which it has not named [2].
- Sept. 29, 2025: the deadline in the administration's letters to drugmakers [2].
Whether Lilly will raise UK prices for other medicines, or whether competing GLP-1 products will follow, has not been reported.
Images from the sources
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.